Coloplast CEO on buying spree: "Something has to happen"

Medtech firm Coloplast is being encouraged to put some of its billions to use, and CEO Kristian Villumsen sort of agrees. But not at any cost.

Photo: Stine Bidstrup/ERH

They've had plenty of bullets, but so far no wish to pull the trigger. Lucrative medtech firm Coloplast is technically on a buying spree, firstly and foremostly in order to strengthen its urology business leg, which needs scale.

"Something has to happen in urology, especially on the side of products and technology, because we haven't invested in innovation for a number of years after the cases we had in the US," says Coloplast CEO Kristian Villumsen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs